Precision Dosing of Doxapram in Preterm Infants Using Continuous Pharmacodynamic Data and Model-Based Pharmacokinetics: An Illustrative Case Series by Poppe, J.A. (Jarinda) et al.
Frontiers in Pharmacology | www.frontiers
Edited by:
Rob ter Heine,
Radboud University Nijmegen
Medical Centre, Netherlands
Reviewed by:
Wei Zhao,
Shandong University, China
Tuuli Metsvaht,
University of Tartu, Estonia
Tamorah Rae Lewis,
Children's Mercy Hospital,
United States
Maarja Hallik,
University of Tartu, Estonia,
in collaboration with reviewer TM
*Correspondence:
Jarinda A. Poppe
j.poppe@erasmusmc.nl
Specialty section:
This article was submitted to
Pharmaceutical Medicine and
Outcomes Research,
a section of the journal
Frontiers in Pharmacology
Received: 17 December 2019
Accepted: 23 April 2020
Published: 12 May 2020
Citation:
Poppe JA, van Weteringen W,
Sebek LLG, Knibbe CAJ, Reiss IKM,
Simons SHP and Flint RB (2020)
Precision Dosing of Doxapram in
Preterm Infants Using Continuous
Pharmacodynamic Data and Model-
Based Pharmacokinetics: An
Illustrative Case Series.
Front. Pharmacol. 11:665.
doi: 10.3389/fphar.2020.00665
ORIGINAL RESEARCH
published: 12 May 2020
doi: 10.3389/fphar.2020.00665Precision Dosing of Doxapram in
Preterm Infants Using Continuous
Pharmacodynamic Data and Model-
Based Pharmacokinetics: An
Illustrative Case Series
Jarinda A. Poppe1*, Willem van Weteringen1,2, Lotte L. G. Sebek3,
Catherijne A. J. Knibbe1,4,5, Irwin K. M. Reiss1, Sinno H. P. Simons1 and Robert B. Flint1,3
1 Department of Pediatrics, Division of Neonatology, Erasmus University Medical Center—Sophia Children's Hospital,
University Medical Center Rotterdam, Rotterdam, Netherlands, 2 Department of Pediatric Surgery, Erasmus University
Medical Center—Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, Netherlands, 3 Department of
Hospital Pharmacy, Erasmus University Medical Center, University Medical Center Rotterdam, Rotterdam, Netherlands,
4 Systems Biomedicine and Pharmacology, Leiden Academic Center for Drug Research, Leiden University, Leiden,
Netherlands, 5 Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein, Netherlands
Introduction: Current drug dosing in preterm infants is standardized, mostly based on
bodyweight. Still, covariates such as gestational and postnatal age may importantly alter
pharmacokinetics and pharmacodynamics. Evaluation of drug therapy in these patients is
very difficult because objective pharmacodynamic parameters are generally lacking. By
integrating continuous physiological data with model-based drug exposure and data on
adverse drug reactions (ADRs), we aimed to show the potential benefit for optimized
individual pharmacotherapy.
Materials and Methods: Continuous data on oxygen saturation (SpO2), fraction of
inspired oxygen (FiO2) and composite parameters, including the SpO2/FiO2 ratio and the
cumulative oxygen shortage under the 89% SpO2 limit, served as indicators for doxapram
effectiveness. We analyzed these continuous effect data, integrated with doxapram
exposure and ADR parameters, obtained in preterm infants around the start of
doxapram therapy. The exposures to doxapram and the active metabolite keto-
doxapram were simulated using a population pharmacokinetic model. Infants were
selected and retrospectively compared on the indication to start doxapram, the first
response to doxapram, a potential dose-response relationship, and the administered
dosage over time. Recommendations were made for individual improvements of therapy.
Results: We provide eight cases of continuous doxapram administration that illustrate a
correct and incorrect indication to start doxapram, responders and non-responders to
therapy, and unnecessary over-exposure with ADRs. Recommendations for improvement
of therapy include: objective evaluation of added effect of doxapram after start, prevention
of overdosing by earlier down-titration or termination of therapy, and the prevention of
hypoxia and agitation by measuring specific parameters at strategical time-points.in.org May 2020 | Volume 11 | Article 6651
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Frontiers in Pharmacology | www.frontiersConclusion: Real-time and non-invasive effect monitoring of drug therapy combined with
model-based exposure provides relevant information to clinicians and can importantly
improve therapy. The variability between and within patients emphasizes the importance
of individual, objective evaluation of pharmacotherapy. These measurements, together
with data on ADRs, allow for precision medicine in neonatology that should be brought to
the bedside.Keywords: precision dosing, doxapram, pharmacokinetic modelling, pharmacodynamics, preterm infantsINTRODUCTION
Most drugs are off-label for use in preterm infants and
administered according to standardized weight-based dosing
regimens, as little is known about the pharmacokinetics (PK)
and pharmacodynamics (PD) (Flint et al., 2018). Maturation of
physiological processes that cause large inter- and intra-
individual variability of PK and PD has hardly been taken into
account (Allegaert and van den Anker, 2014). Parameters to
measure PD in preterm infants are often poorly defined and
depend on clinical observations, which results in subjective
assessment of efficacy and safety. Altogether, these limitations
lead to suboptimal pharmacotherapy in current neonatal care.
Neurological and respiratory underdevelopment in preterm
infants often lead to temporary cessations of breathing, known as
apnea of prematurity. The standard treatment of apnea of
prematurity consists of caffeine (Schmidt et al., 2007) and non-
invasiveventilatory support. If this treatment fails, doxapramcanbe
added as off-label respiratory stimulant to avoid hypoxic periods
which can lead to abnormal brain development (Poets et al., 2015).
Invasive ventilation and the associated risk for bronchopulmonary
dysplasia may be prevented (Vliegenthart et al., 2017b).
The effectiveness of doxapram is currently assessed by
intermittent interpretation of vital sign alarms and nursing
reports. This type of alarm interpretation by clinicians has
been found inconsistent when compared to objectively
analyzed monitor data (Brockmann et al., 2013). Continuous
data on arterial oxygen saturation (SpO2) and administered
fraction of inspired oxygen (FiO2) recently showed potential in
assessing the PD of doxapram (Flint et al., 2017b; Poppe et al.,
2019). Especially composite parameters that reflect oxygen need
(SpO2/FiO2 ratio) and hypoxia (oxygen shortage under the 89%
limit) were found strong indicators of therapy effect (Poppe
et al., 2019).
Information on individual doxapram exposure during
treatment could further improve pharmacotherapy. In the
absence of evidence to support a target plasma concentration,
the burden of invasive blood collections for measurement of
doxapram plasma concentrations is not rational. To overcome
this limitation, a population PK model could serve to simulate
the individual exposure to doxapram and its active metabolite
keto-doxapram (Flint et al., 2019). This simulated exposure
could inform on the variation of clearance with gestational and
postnatal age, and its influence on time to reach a steady state
concentration following therapy start and dose adjustments.in.org 2Adverse drug reactions (ADRs) also need to be taken into
account to titrate doxapram within the individual patient's
therapeutic window. Several ADRs of doxapram have been
reported in preterm infants, including QT interval lengthening
(Maillard et al., 2001) possibly resulting in an atrioventricular
heart block (De Villiers et al., 1998), gastrointestinal problems
(Tay-Uyboco et al., 1991; Maillard et al., 2001), tachycardia
(Barbe et al., 1999), increased electro-encephalographic activity
and less sleep-wake cycling (Czaba-Hnizdo et al., 2014),
irritability and agitation (Tay-Uyboco et al., 1991; Barbe et al.,
1999), and hypokalemia (Fischer et al., 2013; Shimokaze
et al., 2018).
Integrating the continuous effect data with model-based
exposure to doxapram and keto-doxapram, ADR data and
patient characteristics provides the opportunity for model-
informed individual drug dosing. The aim of this study was to
provide these integrated data for individual patients and to show
the potential improvements for doxapram therapy.MATERIALS AND METHODS
Patient Population and Data Collection
A subset of patients from a cohort of 61 preterm infants,
described in an earlier study (Poppe et al., 2019), was selected
for this study. These patients provide various illustrative patient
profiles with respect to the indication, the first response to
doxapram start, the dosing regimen and the dose-response
relationship of doxapram therapy. Patient characteristics were
collected, including the gestational age, postnatal age at therapy
start and post menstrual age at therapy start. Information on the
FiO2, respiratory support mode, doxapram dosages, route of
administration, and doxapram infusion rates was retrieved from
the electronic patient data management system (Picis Clinical
Solutions, Inc., Wakefield, MA, USA). The SpO2, reflecting
effectiveness, was collected (1 Hz) from bedside monitors
(Dräger, Lübeck, Germany). Collected data on ADRs included
heart rate (HR), COMFORTneo scale, Numeric Rating Scale for
agitation (NRS agitation), and potassium serum levels.
Information on HR was collected (1 Hz) from the bedside
monitors. Information on the COMFORTneo scale, NRS
agitation, and potassium serum levels was extracted from the
electronic medical records. Data were collected from 4 days
before therapy start until 7 days after therapy start. The
institutional ethics review board granted a waiver fromMay 2020 | Volume 11 | Article 665
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Subjects Act (WMO) in the Netherlands (MEC-2018-1106).
Adverse Drug Reactions
Available data on ADRs of doxapram included COMFORTneo
scale and NRS agitation as a measure of agitation, and heart rate
to determine tachycardia. Events of agitation were defined as an
NRS agitation ≥4, and as a COMFORTneo scale ≥14 (van Dijk
et al., 2009) in combination with NRS agitation ≥4. The HR was
compared visually with the HR trend in the 4 days before
therapy start.
Doxapram Treatment and Model-Based
PK Simulations
The selected patients were treated according to the local clinical
treatment policy, which states that the attending physicians can
decide to start doxapram treatment at their own discretion. At
therapy start a loading dose of 2.5 mg/kg in 15 min could be
given, followed by a proposed maintenance dose of 2.0 mg/kg/h
by intravenous infusion or continuous gastro-intestinal
administration of the intravenous solution via a nasogastric
tube if enteral feeding was tolerated. The dosage was increased
or decreased by 0.5 mg/kg/h when indicated by the physician.
For each individual patient, the concentration-time profile was
simulated using a population PK model for doxapram and keto-
doxapram in preterm infants with NONMEM V.7.3 (ICON
Development Solutions, Ellicott City, MD, USA) (Flint et al.,
2019). The final pharmacokinetic parameter estimates are given
in Supplementary Table 1. The PK of doxapram was best
described by a two-compartment model with intra-individual
variability on clearance of doxapram through other routes than
formation into keto-doxapram and central volume of
distribution. Keto-doxapram concentrations were also best
described by a two-compartment model. Postnatal age and
gestational age were found to be the best predictors of
maturation of clearance, describing both the elimination
of doxapram through other routes than formation to
keto-doxapram (CLD) and the formation clearance of keto-
doxapram from doxapram (CLD-KD). For an individual of
0.95 kg, gestational age of 25.9 weeks and postnatal age of 17
days, CLD-KD was 0.096 L/h [relative standard error (RSE) 22%]
and CLD was 0.493 L/h (RSE 13%). Oral bioavailability was
estimated at 74%. The exposures to doxapram and keto-
doxapram were simulated in 1-h timeframes.
Data Analysis
The monitor data, the SpO2 and HR, were processed in median
per hour using R software (version 3.5.3., Inc., Boston, MA,
USA). The depth x time <89% SpO2 (cumulative oxygen shortage
<89% limit that reflects hypoxia) was calculated and processed as
absolute number per hour. From these absolute numbers the
mean oxygen shortage per second (%/s) was calculated in a
particular hour. The SpO2/FiO2 ratio was calculated per second
to reflect the oxygen need. This ratio represents the SpO2
corrected for the FiO2, which is the main respiratory support
aside pharmacotherapy. The ratio was processed as median per
hour in the analysis.Frontiers in Pharmacology | www.frontiersin.org 3Evaluation Strategy
The selected patients were evaluated visually on the indication, the
first response to doxapram, the dosing regimen and the
occurrence of ADRs. We re-evaluated the clinical decisions in
retrospect at certain time points (T) and suggested possible
improvements of therapy if these data would have been
available at the bedside for the attending clinicians. The
indication was assessed based on deterioration of the respiratory
condition before therapy start, the level of hypoxia, and the
possibilities to improve the respiratory condition. The first
response was evaluated by the change in hypoxia, oxygen
supply (reflected by the FiO2) and the oxygen need directly after
doxapram start. A patient was classified as responder if hypoxia,
oxygen supply or oxygen need had decreased. The dose-response
relationship was evaluated as a change in the respiratory condition
after dose adjustments. If no dose-response relationship was
found or minimal dose adjustments had been made, the dosing
regimen was defined as overtreatment. Therapy was defined as
failure, if mechanical ventilation was required after therapy stop.RESULTS
Patient Characteristics
Eight patients were selected out of a cohort of 61 preterm infants
who received doxapram therapy. The gestational age of these
selected patients varied between 25.1 and 28.0 weeks, the
postmenstrual age at therapy start varied between 27.6 and 32.8
weeks, and the postnatal age at therapy start varied between 8.5
and 34.0 days (Table 1). In five patients, the mechanical
ventilation had been stopped within 24 h before doxapram start.
Therapy was successful in five of the eight patients.
Integration of Effect Data, Model-Based
Exposure and Adverse Drug Reactions
For all eight cases (A–H), we visualized the effect data, exposure
and ADR parameters before and after doxapram start (Figure 1).
Doxapram and keto-doxapram exposures were provided by
model-based simulated plasma concentrations after therapy
start. The dose adaptations over time were reflected in the
exposure. The suggested possible improvements of therapy are
presented in Table 2.
The Indication of Doxapram Therapy
In the hour before therapy start, the cumulative oxygen
shortage <89% limit varied between 0.3 and 5.1%/s; the FiO2
varied between 21.0 and 47.9%; and the SpO2/FiO2 ratio
varied between 1.9 and 4.6 (Table 3).
In five patients the level of hypoxia had increased before
therapy start, with an increased or equal oxygen supply and
oxygen need (Patients A, B, C, E, F), which indicates that the
patients' conditions deteriorated and the indication to start
therapy could be justified in retrospect. The extubation within
the 24 h before therapy start in three of these patients (Patients B,
E, F) had resulted in an increased level of hypoxia, oxygen supply,
and oxygen need. This respiratory deterioration was also observedMay 2020 | Volume 11 | Article 665
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oxygen supply decreased again before therapy start at T1.
Doxapram was started despite these respiratory improvements,
and the indication to start doxapram could be questioned. Two
other patients (Patients D, H) had no increased level of hypoxia
before doxapram start. In Patient D, the oxygen supply and
oxygen need had not increased before therapy start, and the
level of hypoxia was minimal. In Patient H, oxygen supply, and
consequently oxygen need, had increased before therapy start. As
doxapram was started to prevent hypoxia, the indication for
doxapram seemed incorrect of these two patients (Patients D, H).
Detection of Responders and Non-Responders
The change in the cumulative oxygen shortage <89% limit
between the time-points 1 h before and 4 h after doxapram
start varied between -5.1 and -0.0%/s. The change in the FiO2
varied between -2.0 and 4.2%; the change in the SpO2/FiO2 ratio
varied between -0.1 and 0.6. The individual changes are
presented in Table 3.
We classified four patients as responder to doxapram therapy,
based on the decreased level of hypoxia after therapy start
(Patients A, C, D, G). In two of these (Patients A, C), the
respiratory improvement was also reflected in a decreased
oxygen supply and oxygen need. In Patient D, the effects on
oxygen supply and oxygen need could not be determined as both
were already minimal before therapy start. A small effect of
doxapram was observed in Patient G, although improvement of
the respiratory condition already started already before therapy
start. We classified two patients as potential responder (Patients E,
H), based on a decreased oxygen supply and oxygen need. The
level of hypoxia decreased slightly in Patient E, while the level of
hypoxia was already low before therapy start in Patient H.
Classification of this patient was also impeded due to the large
variability in the oxygen supply and oxygen need. We classified
the two remaining patients as non-responder (Patients B, F). The
decrease in the level of hypoxia was questionable in both patients,
and the oxygen supply and oxygen need increased (Patient F) or
remained equal (Patient B) directly after therapy start.
Dose-Response Relationship
A dose-response relationship was found in two patients (Patients
A, C). A decreased exposure at time-point T3 in Patient A and atFrontiers in Pharmacology | www.frontiersin.org 4T2 in Patient C resulted in a deteriorated respiratory condition
with an increased hypoxia and a larger variability in the oxygen
need. The increased exposure at T4 in Patient A and at T1 in
Patient C decreased the level of hypoxia and the variability in the
oxygen need. Despite multiple dose adjustments in two other
patients (Patients E, H), a dose-response relationship in these
cases was questionable. The increased exposure at T1 in Patient E
did not decrease the hypoxia, although the hypoxia decreased
slightly after the increased exposure at T3 and T5, and increased
after a decreasing exposure at T2 and T4. The hypoxia in Patient
H increased after a decreasing exposure at T1, T2, and T5, and
decreased after an increasing exposure at T4. The large
variability in the oxygen supply and in the oxygen need
complicates the evaluation of the dose-response relationship in
Patient H.
A dose-response relationship was not found in the four
remaining patients (Patients B, D, F, G). In two of these
patients (Patients B, F), minimal dose adjustments had been
made during the treatment period, which made the evaluation of
a dose-response relationship impossible. Regarding the two other
patients, we found no effect of the exposure decrease after down-
titration at T2, T3, T4, and T5 in Patient D and at T2, T3, and T5
in Patient G. Those four patients have probably been overtreated
with doxapram (Patients B, D, F, G).
Adverse Drug Reactions
A remarkable increase in the HR was observed in Patient E after
doxapram start. The HR increased directly after doxapram start
and remained above the baseline HR before therapy start. The
other patients showed no increase in the HR, although the HR
variability increased in Patient A after doxapram start. Two
patients showed some agitation during doxapram therapy
(Patients B, F). The other four patients showed no ADRs
(Patients C, D, G, H), although in Patient C the HR had
decreased after a decreased exposure.
Potential Doxapram Therapy Improvements
per Patient
Patient A
Doxapram therapy could already have been started at T1 to avoid
the hypoxia between T1 and actual therapy start. After day 2 of
doxapram, the dosage was not further down-titrated for another 2TABLE 1 | Baseline characteristics of the subset (n=8).
Patient GA (weeks) PMA (weeks) PNA (days) MV Therapy outcomea ROA Loading dose Maintenance dose (mg/kg/h)b
A 25.1 27.6 17.1 No Success Oral Yes 1.3 ± 0.4
B 26.1 27.8 11.4 Yes Failure IV Yes 1.8 ± 0.4
C 27.0 30.1 21.7 No Success IV Yes 1.9 ± 0.1
D 26.9 31.7 34.0 No Success Oral No 1.3 ± 0.5
E 25.6 27.6 14.1 Yes Failure Oral No 1.4 ± 0.5
F 25.3 27.7 17.0 Yes Failure IV Yes 2.0 ± 0.0
G 28.0 32.8 33.6 Yes Success IV No 1.1 ± 0.3
H 27.6 28.8 8.5 Yes Success Oral Yes 0.9 ± 0.4MayGA, Gestational age; PMA, Postmenstrual age at start of doxapram therapy; PNA, Postnatal age at start of doxapram therapy; MV, Mechanical ventilation in the 24 h before doxapram
start; ROA, Route of administration at start of doxapram therapy; IV, Intravenous.
aTherapy failure was defined as the need for mechanical ventilation after therapy stop.
bMaintenance dose during the study period (mean ± SD).2020 | Volume 11 | Article 665
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FIGURE 1 | Data on doxapram effect, exposure and ADRs are visualized of the eight selected preterm infants (A–H). Doxapram effect is reflected by the oxygen
saturation (SpO2), fraction of inspired oxygen (FiO2), the oxygen shortage <89% SpO2 limit, and the SpO2/FiO2 ratio. Doxapram and keto-doxapram exposures were
simulated from a population pharmacokinetic model. The NRS agitation, COMFORTneo scale, and heart rate reflected the adverse drug reactions agitation and
tachycardia. Specific time-points were marked (T). ADRs, adverse drug reactions; NRS agitation, Numeric Rating Scale agitation.Frontiers in Pharmacology | www.frontiersin.org May 2020 | Volume 11 | Article 6656
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overdosing. Therapy should have been evaluated more strictly,
every 12 h, and the dosage should have been decreased sooner
(Figure 1A).
Patient B
Judging from the effect data, mechanical ventilation should have
started a day after therapy start, as no response to doxapram was
seen. This could have prevented doxapram overtreatment, the
agitation around day 2 and unnecessary hypoxia (Figure 1B).
Patient C
Although the oxygen supply and the variability of the oxygen
need increased after a dose reduction at T2, no dose adjustments
were made for at least 5 days. Therapy should have been
evaluated at least every 12 h, and the dosage should have been
increased to prevent hypoxia (Figure 1C).
Patient D
The continuous effect data showed no reason to start doxapram
therapy, and bedside availability of the data could have prevented
this. The first down-titration was done at T2, 1.5 days after therapy
start. The doxapram dosage should have been down-titrated every
12 h, starting at T1. This would likely have prevented unnecessary
long doxapram therapy (Figure 1D).Frontiers in Pharmacology | www.frontiersin.org 7Patient E
The HR increased directly after therapy start in this patient. As
periods of hypoxia still occurred during doxapram therapy and
the HR increased, mechanical ventilation should have been
started earlier to prevent hypoxia and ADRs (Figure 1E).
Patient F
The level of agitation was scored higher during doxapram therapy
and the exposure to doxapram was relatively high. Judging from
these data, we suggest that mechanical ventilation should have been
resumed earlier, at least before T1, to prevent hypoxia and ADRs
(Figure 1F).
Patient G
The dosage should have been decreased again at T4 to prevent
overtreatment. In general, we would suggest to decrease the dosage
every 12 h if a patient's respiratory condition has not deteriorated
(Figure 1G).
Patient H
Due to the large variability in the effect parameters the indication,
first response and dose-response relationship were difficult to
evaluate. The dosage should have been increased again at T3 and
the therapy effect should have been evaluated more strictly, at least
every 12 h, in the following treatment period (Figure 1H).TABLE 2 | Overview of the retrospective evaluation and recommendations for improvements.
Patient Indication First
response
Dosing regimen ADRsa Potential improvements with bedside availability
A Correct Responder Dose-response
relationship
Increased heart rate
variability
Start therapy earlier to prevent hypoxia and decrease dosage every 12 h
to prevent overtreatment
B Correct Non-
responder
Overtreatment Increased agitation Stop therapy earlier to prevent hypoxia and overtreatment with ADRs
C Correct Responder Dose-response
relationship
No ADRs observed Evaluate therapy effect at least every 12 h and increase dosage to
prevent hypoxia
D Incorrect Responder Overtreatment No ADRs observed Do not start doxapram therapy, and decrease dosage every 12 h to
prevent overtreatment
E Correct Potential
responder
Potential dose-response
relationship
Increased heart rate Stop therapy earlier to prevent hypoxia and overtreatment with ADRs
F Correct Non-
responder
Overtreatment Increased agitation Stop therapy earlier to prevent hypoxia and overtreatment with ADRs
G Probably
correct
Responder Overtreatment No ADRs observed Decrease dosage every 12 h to prevent overtreatment
H Probably
incorrect
Potential
responder
Potential dose-response
relationship
No ADRs observed Evaluate therapy effect at least every 12 h to prevent hypoxiaaPossible adverse drug reaction (ADR).TABLE 3 | The individual values at 1 h before doxapram, and the changes from 1 h before until 4 h after doxapram start.
Patient Oxygen shortage (%/s)a FiO2 (%)
a SpO2/FiO2 ratio
a Δ Oxygen shortage (%/s)b Δ FiO2 (%)
b Δ SpO2/FiO2 ratio
b
A 2.9 24.0 3.67 -2.8 -1.0 0.58
B 2.1 47.9 1.90 -1.7 1.9 0.04
C 2.2 26.0 3.58 -2.1 -2.0 0.54
D 0.3 21.0 4.61 -0.2 0.0 -0.03
E 5.1 41.5 2.08 -5.1 0.3 0.19
F 4.3 34.3 2.56 -4.1 4.3 -0.14
G 1.9 21.0 4.38 -1.8 0.0 0.27
H 0.3 26.0 3.57 -0.0 -1.5 0.14May 2020 | VolaOne hour before doxapram start.
bChange from 1 h before until 4 h after doxapram start.ume 11 | Article 665
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This study showed that pharmacotherapy may be improved with
the real-time availability of continuous monitor data integrated
with model-informed exposure data, and ADR parameters.
Using this approach, we could suggest several improvements
for doxapram therapy for eight illustrative preterm infants.
Access to these data at the bedside can support clinicians to
adequately indicate and evaluate therapy. This may reduce
overdosing, unnecessary long treatment, suboptimal treatment
and the occurrence of ADRs. The inter-individual differences in
the observed data trends and patterns advocate an individualized
approach. Real-time effect evaluation supports the attending
physician in identifying patients for whom doxapram will
be effective.
In all studies reporting apnea rate in preterm infants,
doxapram therapy led to fewer cases of apnea (Vliegenthart
et al., 2017a). A positive effect of doxapram and—to a lesser
extent of keto-doxapram—on the respiratory drive was also
found in newborn lambs (Bairam et al., 1990). Two
retrospective studies concluded that doxapram therapy may
avoid mechanical ventilation (Prins et al., 2013; Flint et al.,
2017a). In our earlier studies, doxapram therapy had a positive
effect on the SpO2, the applied FiO2 (Flint et al., 2017b), the
oxygen need (SpO2/FiO2 ratio), and hypoxia (cumulative oxygen
shortage under the 89% limit) (Poppe et al., 2019). The present
study is the first in which doxapram therapy effects were
continuously evaluated in individual patients.
If integrated data would have been continuously available,
several patients could have been prevented from unnecessarily
long doxapram treatment (Patients B, D, F, G), hypoxia (Patients
B, C, E, F, H), and overdosing (Patient F). Even without a
doxapram target concentration, visualizing the exposures to
doxapram and keto-doxapram will be relevant to monitor
dosage adjustments and an expected new steady state. The
exposure could also be predicted a few hours ahead to support
dosage adjustments. In this study, the simulated data from the PK
model could only be used to explain, and not to predict the clinical
outcomes, as data were collected retrospectively. Furthermore,
visualized exposure permits detection of the individual
relationships with therapy effectiveness or ADRs, which could
serve as an individual target for therapy. An individual target is in
particular important for doxapram therapy as dosing regimens
have been based on body weight, while exposure is related to the
gestational age and postnatal age (Flint et al., 2019). A measured
plasma concentration of doxapram and keto-doxapram would
make the simulated exposure from the PKmodel more accurate as
inter-patient variability is taken into account.
In addition to the effectiveness and drug exposure, our study
suggests the integration of ADRs into routine evaluation of
pharmacotherapy. Although some ADRs of doxapram have
been described in neonates (Tay-Uyboco et al., 1991; De Villiers
et al., 1998; Barbe et al., 1999; Maillard et al., 2001; Fischer et al.,
2013; Czaba-Hnizdo et al., 2014; Shimokaze et al., 2018), the
results of these studies were not conclusive, and sample sizes were
small in most studies. In our study, we found that ADRFrontiers in Pharmacology | www.frontiersin.org 8parameters were underreported, in part because they had not
been specifically registered to assess ADRs of doxapram. The
occurrence of hypokalemia could not be evaluated, for example,
because potassium serum levels in the study period were not
available for all eight patients. This can be explained by
unawareness of clinicians about drug specific ADRs. Next to
under detection, underreporting of ADRs is also a common
problem, as well in adult clinical care, and could be improved
with automated ADR detection systems (McMaster et al., 2019).
Causality between pharmacotherapy and a potential ADR is
often difficult in preterm infants as most potential ADRs are
difficult to distinguish from common complications related to
preterm birth itself (Allegaert and van den Anker, 2015). Drug
specific and routine assessment of ADRs has not been
implemented in neonatal intensive care treatment, although
important steps have recently been made to interpret possible
ADRs (Salaets et al., 2019). Defining adequate ADR parameters
and registering these around each dose adjustment would
improve ADR evaluation. The projection of possible ADRs
likely improves the recognition and may create more
awareness to evaluate and register ADRs.
The large differences in response to doxapram between the
eight selected patients illustrate the need to explore individual
risk-benefit profiles. Some patients showed respiratory
improvement directly after doxapram start, while others did not
show a response at all. Identifying predictors of non-response to
doxapram therapy can prevent unnecessary doxapram treatment
and therewith suboptimal therapy and possible harm. The first
response to doxapram therapy can already inform the clinician on
therapy outcome. Previously we have found that the SpO2/FiO2
ratio in the 48 h around start of doxapram, corrected for postnatal
age and mechanical ventilation before therapy start, was a
predictor for therapy failure or success (Poppe et al., 2019).
Clearance, and the related exposure and effect, may differ from
the general preterm population in, for instance, those small for
gestational age with different severity of illness and co-medication
(Allegaert et al., 2017).
Doxapram is indicated as an additional therapy to non-
invasive ventilation, oxygen supply and caffeine treatment. In
part, all therapies share the same effect and aim to protect the
newborn against hypoxia. These co-interventions need, therefore,
to be taken into account in the effect evaluation of doxapram
therapy. The FiO2 was already used to assess the doxapram effects,
and the effect of non-invasive mode seems limited (Figure 1). In
Patient C (Figure 1C), however, it is challenging to distinguish the
effect of doxapram from the respiratory support as CPAP was
switched to NIPPV just before doxapram start. Data on apneas
could partly correct for the influence of these confounders, but the
detection of apneas remains challenging and the definition varies
between centers. Additionally, in the majority of patients no
relationship could be observed between PK and PD. This
finding points out that there are still unknown factors that
influence the PK, PD, or both. The factors that change the
respiratory status could be respiratory support and coexisting
medical conditions such as infections, patent ductus arteriosus,
and feeding problems. Identification of these factors is essentialMay 2020 | Volume 11 | Article 665
Poppe et al. Model-Based Precision Dosing of Doxaprambefore individual dose titration for targeting a PD effect, based on
a PKPD relationship, can be implemented into clinical practice.
Tachycardia is a potential ADR of both doxapram and caffeine.
A previous study found more tachycardia in preterm infants with
high caffeine dosage than in those with low caffeine dosage (Chen
et al., 2018). All eight selected patients in the present study were
treated with caffeine. To further improve the treatment of hypoxia,
the administered caffeine dosages and the caffeine exposure
should be integrated in the data as well. Also, pharmacokinetic
interactions may occur with co-medication and influence the
clearance of doxapram. Fluconazole, for example, which is used
to protect preterm infants from fungal infections, is an inhibitor of
CYP3A4 and will decrease the clearance of doxapram that is
mainly metabolized by this enzyme (Ogawa et al., 2015).
Real-time monitoring with integrated data may also be used
for other drugs. Vinks et al. recently provided a real-time bedside
decision support system with drug exposure and response for
morphine administration in neonatal pain management (Vinks
et al., 2019). The safety of morphine could be monitored using
continuous physiological data (Hartley et al., 2018). For all drugs
and indications objective PD parameters are needed to apply this
concept. This is challenging in drugs such as fentanyl and
analgesia, but new developments in continuous pain
measurements may be helpful (Moultrie et al., 2017).
The continuous collection of data on effect, exposure and ADRs
could be suitable for automatic dosing systems. Our findings urge
caution, however. We found large differences in the PK and PD of
doxapram within and between patients, which preclude defining
the optimal effect and target concentration. Both the optimal effectFrontiers in Pharmacology | www.frontiersin.org 9and the target concentration are likely to change over time.
Consequently, the dose-response relationship may change over
time. Thus, the concept of automated adjustments on the basis of
effect parameters still belongs to a distant future. Until then, the
responsibility for both interpretation of all data streams and the
adjustment of pharmacotherapy remains with the clinician.
In clinical practice, the implementation of individualized
evaluation of continuous data may lead to the following events.
Imagine an extremely preterm infant who was extubated earlier
for 12 h after several days of invasive ventilation. The infant
shows frequent apneas, oxygen desaturations and is at risk for re-
intubation. The clinician decides to start doxapram therapy, but
the real-time effect data show no signs of improvement. The
model-informed exposure indicates that it takes 8 h to reach
steady state exposure. The monitor trend alerts, however, warn
that the infant is more agitated with increased tachycardia even
before the model-informed exposure has reached steady state.
These data assist the clinician in making the decision to stop
doxapram therapy and to re-intubate this individual infant. This
case illustrates how simulation of the exposure resulting from a
considered dose adjustment at the bedside is likely to be helpful
in targeting blood concentrations in individual patients, avoiding
ADRs and optimizing effectiveness, as illustrated in Figure 2.CONCLUSION
Current pharmacotherapy for preterm infants is suboptimal and
could be improved by continuously collecting monitor data,FIGURE 2 | In addition to current clinical care, in which the clinician actuates a dosing regimen, model-based simulated exposure of considered dose adjustments is
added. This offers simulation of doxapram and keto-doxapram exposures, adjusted to the individual patient. The interpretation of this information and actuation of
changes still resides with the clinician, who can be presented extensive information on adverse drug reactions and effect parameters. NRS agitation, Numeric Rating
Scale agitation; SpO2, oxygen saturation; FiO2, fraction of inspired oxygen.May 2020 | Volume 11 | Article 665
Poppe et al. Model-Based Precision Dosing of Doxaprammodel-informed exposure and ADR parameters. Data collection
and evaluation of more doxapram patients in the future will
improve the classification and recognition of responders and
non-responders. The concept of individualized evaluation of
continuous data should be implemented in clinical care.DATA AVAILABILITY STATEMENT
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